The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study
Background. Lung fibrosis is a sequela of COVID-19 among patients with severe pneumonia. Idiopathic pulmonary fibrosis and lung fibrosis due to COVID-19 may share many similar features. There are limited data on effects of antifibrotic treatment of infection-related lung fibrosis. This study aimed t...
Saved in:
Main Authors: | Narongkorn Saiphoklang, Pimchanok Patanayindee, Pitchayapa Ruchiwit |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Critical Care Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2022/9972846 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevalence of pulmonary arterial hypertension in post-tuberculosis lung fibrosis patients: A cross-sectional observational study
by: Rupak Chatterjee, et al.
Published: (2023-12-01) -
Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report
by: Stefanie Klampfleitner, et al.
Published: (2025-01-01) -
Regulatory T Cell Phenotype Related to Cytokine Expression Patterns in Post‐COVID‐19 Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis
by: Sara Gangi, et al.
Published: (2025-01-01) -
Surveying the aftermath: a qualitative and semiquantitative study of post-COVID-19 sequelae in the lungs
by: Kurian C. Eapen, et al.
Published: (2025-01-01) -
Role of IPF genetic risk loci in post-COVID-19 lung abnormalities: a cohort study
by: James Johnston, et al.
Published: (2025-01-01)